In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients: a 6-Year Survey

Margo Olbrecht; Fedoua Echahidi; Denis Piérard; Charlotte Peeters; Peter Vandamme; Ingrid Wybo; Thomas Demuyser

doi:10.1128/aac.00379-23

In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients: a 6-Year Survey

Margo Olbrecht, Fedoua Echahidi, Denis Piérard, Charlotte Peeters, Peter Vandamme, Ingrid Wybo, Thomas Demuyser

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

We conducted in vitro antimicrobial susceptibility testing of 267 Achromobacter isolates for 16 antibiotics from 2017 to 2022. The highest susceptibility was found for piperacillin-tazobactam (70%) and ceftazidime-avibactam (62%). Between 30% and 49% of strains were susceptible to tigecycline, ceftazidime, and meropenem. We applied species-specific Achromobacter xylosoxidans breakpoints for piperacillin-tazobactam, meropenem, and trimethoprim-sulfamethoxazole and EUCAST pharmacokinetic/pharmacodynamic (PK/PD) breakpoints for the others. A. xylosoxidans was the most frequently isolated species, followed by Achromobacter insuavis and Achromobacter ruhlandii.

Original language	English
Article number	e0037923
Number of pages	6
Journal	Antimicrobial Agents and Chemotherapy
Volume	67
Issue number	7
DOIs	https://doi.org/10.1128/aac.00379-23
Publication status	Published - 18 Jul 2023

Bibliographical note

Publisher Copyright:
Copyright © 2023 American Society for Microbiology.

Keywords

Achromobacter
In vitro susceptibility
antibiotic resistance
cystic fibrosis

Access to Document

10.1128/aac.00379-23

Cite this

@article{251019e33de147a88dce0c23b298745d,

title = "In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients: a 6-Year Survey",

abstract = "We conducted in vitro antimicrobial susceptibility testing of 267 Achromobacter isolates for 16 antibiotics from 2017 to 2022. The highest susceptibility was found for piperacillin-tazobactam (70%) and ceftazidime-avibactam (62%). Between 30% and 49% of strains were susceptible to tigecycline, ceftazidime, and meropenem. We applied species-specific Achromobacter xylosoxidans breakpoints for piperacillin-tazobactam, meropenem, and trimethoprim-sulfamethoxazole and EUCAST pharmacokinetic/pharmacodynamic (PK/PD) breakpoints for the others. A. xylosoxidans was the most frequently isolated species, followed by Achromobacter insuavis and Achromobacter ruhlandii.",

keywords = "Achromobacter, In vitro susceptibility, antibiotic resistance, cystic fibrosis",

author = "Margo Olbrecht and Fedoua Echahidi and Denis Pi{\'e}rard and Charlotte Peeters and Peter Vandamme and Ingrid Wybo and Thomas Demuyser",

note = "Publisher Copyright: Copyright {\textcopyright} 2023 American Society for Microbiology.",

year = "2023",

month = jul,

day = "18",

doi = "10.1128/aac.00379-23",

language = "English",

volume = "67",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "7",

}

In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients : a 6-Year Survey. / Olbrecht, Margo; Echahidi, Fedoua ; Piérard, Denis; Peeters, Charlotte; Vandamme, Peter; Wybo, Ingrid ; Demuyser, Thomas.

In: Antimicrobial Agents and Chemotherapy, Vol. 67, No. 7, e0037923, 18.07.2023.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients

T2 - a 6-Year Survey

AU - Olbrecht, Margo

AU - Echahidi, Fedoua

AU - Piérard, Denis

AU - Peeters, Charlotte

AU - Vandamme, Peter

AU - Wybo, Ingrid

AU - Demuyser, Thomas

PY - 2023/7/18

Y1 - 2023/7/18

N2 - We conducted in vitro antimicrobial susceptibility testing of 267 Achromobacter isolates for 16 antibiotics from 2017 to 2022. The highest susceptibility was found for piperacillin-tazobactam (70%) and ceftazidime-avibactam (62%). Between 30% and 49% of strains were susceptible to tigecycline, ceftazidime, and meropenem. We applied species-specific Achromobacter xylosoxidans breakpoints for piperacillin-tazobactam, meropenem, and trimethoprim-sulfamethoxazole and EUCAST pharmacokinetic/pharmacodynamic (PK/PD) breakpoints for the others. A. xylosoxidans was the most frequently isolated species, followed by Achromobacter insuavis and Achromobacter ruhlandii.

AB - We conducted in vitro antimicrobial susceptibility testing of 267 Achromobacter isolates for 16 antibiotics from 2017 to 2022. The highest susceptibility was found for piperacillin-tazobactam (70%) and ceftazidime-avibactam (62%). Between 30% and 49% of strains were susceptible to tigecycline, ceftazidime, and meropenem. We applied species-specific Achromobacter xylosoxidans breakpoints for piperacillin-tazobactam, meropenem, and trimethoprim-sulfamethoxazole and EUCAST pharmacokinetic/pharmacodynamic (PK/PD) breakpoints for the others. A. xylosoxidans was the most frequently isolated species, followed by Achromobacter insuavis and Achromobacter ruhlandii.

KW - Achromobacter

KW - In vitro susceptibility

KW - antibiotic resistance

KW - cystic fibrosis

UR - http://www.scopus.com/inward/record.url?scp=85164843603&partnerID=8YFLogxK

U2 - 10.1128/aac.00379-23

DO - 10.1128/aac.00379-23

M3 - Article

C2 - 37310234

VL - 67

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

M1 - e0037923

ER -

In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients: a 6-Year Survey

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this